Inhibikase Therapeutics Adds Clinical Expert to Board
The appointment of Scott Wasserman brings additional oversight to the biotech firm's ongoing clinical development operations.
Updated on Oct. 20, 2026 in People
Live Poll
Do you trust that new board appointments improve a company's success in developing new drugs?
Inhibikase Therapeutics has appointed Scott Wasserman to its Board of Directors, effective October 19, 2026. The move follows the resignation of Dennis Berman from the Wilmington-based firm.
Why it matters
Inhibikase is leaning into specialized medical leadership to bolster its clinical development pipeline, a standard strategic pivot for small-cap biotech firms navigating the complex regulatory requirements of drug trials.
The firm, currently managing a portfolio that includes the 180-site IMPROVE-PAH clinical study, has added a director with two decades of experience. The impact on the company's oversight of the treatment for a condition affecting 50,000 Americans remains to be determined.
The players
Scott Wasserman
A clinical development veteran and the current Chief Medical Officer of Kailera Therapeutics.
Dennis Berman
An outgoing director who recently resigned from the Inhibikase Board of Directors.
Inhibikase Therapeutics
A Wilmington-based biotechnology company focused on clinical drug development.
The details
Scott Wasserman transitions to the Inhibikase board while concurrently serving as the Chief Medical Officer at Kailera Therapeutics. His background includes previous executive leadership roles at Amgen and Latigo Biotherapeutics, as well as an academic tenure at Stanford University. The board appointment integrates this clinical development expertise directly into the company’s governance structure.
Timeline
October 19, 2026: Scott Wasserman officially joined the Board of Directors.
October 20, 2026: The company formally announced the change in board composition.
Market Landscape
The leadership change follows the pattern of small-cap biotechs professionalizing their governance to match the demands of active, large-scale clinical trials. It aligns with the operational requirements of the ongoing 180-site IMPROVE-PAH clinical study.
Operators in the biotech space should track whether this board shift signals a change in the company's clinical trial pacing or focus. Investors and partners should watch for how this expertise influences the management of the 180-site IMPROVE-PAH study.
The takeaway
Board transitions often indicate a company's shifting priorities toward specific clinical or regulatory milestones. Operators should track how the incoming director’s background in clinical development translates into revised study timelines or operational scale for the company’s pipeline.
Further reading
For more on shifts in local corporate leadership, visit People.
Live Poll
Do you trust that new board appointments improve a company's success in developing new drugs?
